Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine

Atherosclerosis

Volumn 204, Issue 2, 2009, Pages 412-417

  Riederer, Monika ^a,b   Erwa, Wolfgang ^b   Zimmermann, Robert ^a   Frank, Saša ^b   Zechner, Rudolf ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adipose tissue; Atherosclerosis; Homocysteine; Methyltransferase; Nicotinamide; Nicotinic acid; NNMT

Indexed keywords

HOMOCYSTEINE; NICOTINAMIDE METHYLTRANSFERASE; NICOTINIC ACID;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; ANTILIPEMIC AGENTS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOMOCYSTEINE; HUMANS; MALE; MICE; MICE, INBRED C57BL; NIACIN; NIACINAMIDE; NICOTINAMIDE N-METHYLTRANSFERASE; RNA, MESSENGER; TIME FACTORS;

EID: 67349224402     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.09.015     Document Type: Article

References (37)

1. Aksoy S., Szumlanski C.L., and Weinshilboum R.M. Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem 269 (1994) 14835-14840
2. Aksoy S., Brandriff B.F., Ward A., Little P.F., and Weinshilboum R.M. Human nicotinamide N-methyltransferase gene: molecular cloning, structural characterization and chromosomal localization. Genomics 29 (1995) 555-561
3. Castro R., Rivera I., Blom H.J., Jakobs C., and Tavares de Almeida I. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit Metab Dis 29 (2006) 3-20
4. Verhoef P., Kok F.J., Kruyssen D.A., et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997) 989-995
5. Till U., Rohl P., Jentsch A., et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12. Atherosclerosis 181 (2005) 131-135
6. Souto J.C., Blanco-Vaca F., Soria J.M., et al. A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project. Am J Hum Genet 76 (2005) 925-933
7. Seifert R., Hoshino J., and Kroger H. Nicotinamide methylation. Tissue distribution, developmental and neoplastic changes. Biochim Biophys Acta 801 (1984) 259-264
8. Alston T.A., and Abeles R.H. Substrate specificity of nicotinamide methyltransferase isolated from porcine liver. Arch Biochem Biophys 260 (1988) 601-608
9. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258 (2005) 94-114
10. Shepherd J., Packard C.J., Patsch J.R., Gotto Jr. A.M., and Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 63 (1979) 858-867
11. Meyers C.D., Kamanna V.S., and Kashyap M.L. Niacin therapy in atherosclerosis. Curr Opin Lipidol 15 (2004) 659-665
12. Tunaru S., Kero J., Schaub A., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9 (2003) 352-355
13. Rubin C.S., Lai E., and Rosen O.M. Acquisition of increased hormone sensitivity during in vitro adipocyte development. J Biol Chem 252 (1977) 3554-3557
14. Rubin C.S., Hirsch A., Fung C., and Rosen O.M. Development of hormone receptors and hormonal responsiveness in vitro. Insulin receptors and insulin sensitivity in the preadipocyte and adipocyte forms of 3T3-L1 cells. J Biol Chem 253 (1978) 7570-7578
15. Rini J., Szumlanski C., Guerciolini R., and Weinshilboum R.M. Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation. Clin Chim Acta 186 (1990) 359-374
16. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
17. Tuschl K., Bodamer O.A., Erwa W., and Muhl A. Rapid analysis of total plasma homocysteine by tandem mass spectrometry. Clin Chim Acta 351 (2005) 139-141
18. Dierkes J., and Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 5 (2005) 124-139
19. Dierkes J., Westphal S., and Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 3 (2004) 101-111
20. Austin R.C., Lentz S.R., and Werstuck G.H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11 Suppl 1 (2004) S56-S64
21. Sharma P., Senthilkumar R.D., Brahmachari V., et al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis 5 (2006) 1
22. Haynes W.G. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 16 (2002) 391-399
23. Scheller T., Orgacka H., Szumlanski C.L., and Weinshilboum R.M. Mouse liver nicotinamide N-methyltransferase pharmacogenetics: biochemical properties and variation in activity among inbred strains. Pharmacogenetics 6 (1996) 43-53
24. Carlson L.A., and Oro L. Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis 18 (1973) 1-9
25. Carlson L.A., and Wahlberg G. Relative increase in apolipoprotein CII content of VLDL and chylomicrons in a case with massive type V hyperlipoproteinaemia by nicotinic acid treatment. Atherosclerosis 31 (1978) 77-84
26. Gurakar A., Hoeg J.M., Kostner G., Papadopoulos N.M., and Brewer Jr. H.B. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 57 (1985) 293-301
27. Walldius G., and Wahlberg G. Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis. Adv Exp Med Biol 183 (1985) 281-293
28. Hernandez M., Wright S.D., and Cai T.Q. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun 355 (2007) 1075-1080
29. Kang-Lee Y.A., McKee R.W., Wright S.M., Swendseid M.E., Jenden D.J., and Jope R.S. Metabolic effects of nicotinamide administration in rats. J Nutr 113 (1983) 215-221
30. Carlson L.A., and Hanngren A. Initial distribution in mice of 3H-labeled nicotinic acid studied with autoradiography. Life Sci 3 (1964) 867-871
31. Perla-Kajan J., Twardowski T., and Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 32 (2007) 561-572
32. Guthikonda S., and Haynes W.G. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 8 (2006) 100-106
33. Wierzbicki A.S. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 4 (2007) 143-150
34. Kothekar M.A. Homocysteine in cardiovascular disease: a culprit or an innocent bystander?. Indian J Med Sci 61 (2007) 361-371
35. Hosoi T., Sasaki M., Miyahara T., et al. Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol (2008)
36. Li Y., Jiang C., Xu G., et al. Homocysteine upregulates resistin production from adipocytes in vivo and in vitro. Diabetes 57 (2008) 817-827
37. Masaki T., Anan F., Anai M., et al. Hyperhomocysteinemia is associated with visceral adiposity in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 77 (2007) 168-173